BioMed Nexus Update: Feb 14 News & Tools

Daily Updates

Sentivera Launches With a $1.5B Haisco Inflammation Deal as Biotech IPOs Near Escape Velocity (August 26, 2026)

Last updated: August 26, 2026. ARCH and Population Health Partners launched Sentivera with a Haisco type 2 inflammation license worth $75.89 million upfront and up to $1.46 billion in milestones, while 25 biotech IPOs priced in 2026 have a Leerink banker calling the market close to escape velocity. This page covers the Sentivera deal structure, the IPO window’s quality bar, the Amylyx closing watch, the UK oral obesity launch, Cellares layoffs, and the Medicare litigation rulings.

Daily Updates

Capricor’s Deramiocel Gets a November 22 PDUFA Date and a Narrower Label Ask as Roche Bets Up to $2.3B on Hanmi’s Muscle Preserving Obesity Drug (August 25, 2026)

Last updated: August 25, 2026 The FDA moved Capricor’s deramiocel decision to November 22, 2026 after classifying new HOPE-3 extension data as a major amendment, while Genentech licensed Hanmi’s muscle preserving obesity candidate HM17321 for $190 million upfront and up to $2.3 billion total. This

Daily Updates

Capricor’s August 22 PDUFA Date Passed With No Public FDA Action as an Activist Pushed for a Board Overhaul and Arbutus Launched a $230M Buyback, August 24, 2026

Last updated: August 24, 2026 Capricor’s August 22, 2026 PDUFA target action date for deramiocel passed with no public FDA action and no company statement. Activist investor Kaos Capital demanded a board overhaul on August 21. Arbutus Biopharma launched a $230 million Dutch auction tender

BioMed Nexus Update: Feb 14 News & Tools

Table of Contents

Featured Articles

Sentivera Launches With a $1.5B Haisco Inflammation Deal as Biotech IPOs Near Escape Velocity (August 26, 2026)

Capricor’s Deramiocel Gets a November 22 PDUFA Date and a Narrower Label Ask as Roche Bets Up to $2.3B on Hanmi’s Muscle Preserving Obesity Drug (August 25, 2026)

Capricor’s August 22 PDUFA Date Passed With No Public FDA Action as an Activist Pushed for a Board Overhaul and Arbutus Launched a $230M Buyback, August 24, 2026

BioMed Nexus Update: Feb 14 News & Tools

Table of Contents

Featured Articles

Sentivera Launches With a $1.5B Haisco Inflammation Deal as Biotech IPOs Near Escape Velocity (August 26, 2026)

Capricor’s Deramiocel Gets a November 22 PDUFA Date and a Narrower Label Ask as Roche Bets Up to $2.3B on Hanmi’s Muscle Preserving Obesity Drug (August 25, 2026)

Capricor’s August 22 PDUFA Date Passed With No Public FDA Action as an Activist Pushed for a Board Overhaul and Arbutus Launched a $230M Buyback, August 24, 2026

Join 65,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morningBreakthroughs, trial data, deals, and the news that matters

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters